
Emestedastat did not significantly slow disease progression, but a prespecified analysis showed a higher rate of zero CDR-SB progression.
What effect will aducanumab have on Alzheimer disease treatment?
RJ Tesi, MD, discusses the recent aducanumab FDA approval and the implications it will have on the treatment of Alzheimer disease.
Dr Tesi is CEO and Chief Medical Officer of


